4Jung K,Pergande M,Schimke E,et al . Urinary enzymes and low- molecular-mass proteins as indicators of diabetic nephropathy [J] . Clin Chem, 1988,34,544.
5Marcussen N, Schumann J, Campbell P, Kjellstrand C. Cytodiagnostic urinalysis is very useful in the differential diagnosis of acute renal failure and can predict the severity [J] . Ren Fail, 1995 Nov, 17(6): 721-729.
6Fogazzi GB,Saglimbeni L,Banfi G,et al . Urinary sediment features in proliferative and non-proliferative glomerular diseases [J] . J Nephrol,2005 Nov-Dec, 18(6):703-710.
7Guido T. Multiple myeloma and other plasma cell disorders [M]// Hoffman R. Hematology-hasic principles and practice. 4th ed. Elsevier, 2005 : 1501-1505.
8Sakhuja V, Jha V, Varma S, et al. Renal involment in multiple myeloma: 10 years study,Ren Fail, 2000, 22(4):465-477.
9Knudsen LM, Hippe E, Hjorth M, Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol,1994,53(4):207-212.
10Sanders PW, Herrera GA, Galla JH. Human Benee Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int, 1987, 32(6) :851-861.
7Heidtmann HH, Salge U, Abrahamson M, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines [J]. Clin Exp Metastasis, 1997,15 (4) : 368-381.
8Kos J, Stabuc B, Cimeiman N, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression[ J ]. Clin Chem, 1998,44(12) : 2556-2557.
9Terpos E, Katodritou E, Tsiftsakis E,et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration [J]. Haematologica,2009, 94(3):372-379.
10de Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonu- cleotide arrays [ J ]. Oncogene, 2002,21 (44) : 6848-6857.
